Pregnancy Cohort in Multiple Sclerosis (MS)

NCT05010902 · tracked via the Priya Life Science Germany tracker

Sponsor

Charite University, Berlin, Germany

Phase

Observational

Started

2013-01-01

Last updated

2024-07-05

Condition(s) studied

Multiple Sclerosis (MS)Clinically Isolated Syndrome (CIS)

Study summary

Multiple sclerosis (MS) is a common inflammatory demyelinating disorder of the central nervous system frequently affecting females in their reproductive phase of life. In this prospective observational study, we obtain data on the outcome of pregnancies in MS patients and the influence of pregnancy on clinical, laboratory and MRI parameters in MS.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

50 Years

Healthy volunteers

Accepted

Inclusion Criteria: * age \> 18 years * signed informed consent * diagnosis of multiple sclerosis or clinically isolated syndrome Exclusion Criteria: * clinically relevant comorbidities * contraindications for MRI, e.g. pacemaker, metal implants, allergy against gadolinium * alcohol or drug abuse

Primary outcome measure(s)

Time until relapse — 12 months after delivery compared to baseline
Time (in days) until relapse during the observation period

Trial sites (1)

Facility	City	Region	Status
Charité Universitätsmedizin Berlin	Berlin	Germany	Recruiting

More Charite University, Berlin, Germany trials in Germany

Master Study Protocol for the Cohort of the Specialist Network Stroke (SN Stroke)(Stroke-CORE) Starting soon

Berlin-Brandenburg Pregnancy Cohort Recruiting

Prospective Validation Study of the CD8+TEMRA Cells As a Prognostic Biomarker of Healing Outcome After Fracture Recruiting

Quality Contract: Prevention of Postoperative Delirium in the Care of Older Patients (QV-POD-2) Recruiting

Establishment of 2D and 3D Primary Cell Cultures From Gastric and Gastroesophageal Junction Cancer Starting soon

Other trials for the same condition

Kappa Free Light Chains (KFLC) in Multiple Sclerosis (MS) and Clinically Isolated Syndrome (CIS) Enrolling by invitation

Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05010902 on ClinicalTrials.gov ↗ ← All trials in Germany